SGS Expands Biomarker Testing Capabilities at Poitiers Facility

February 24, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-03-04-2015, Volume 11, Issue 3

SGS has invested in additional modules for its COBAS 6000 analysis system in a move to expand its biomarker analytical capabilities at its Poitiers facility in France.

SGS announced that it has invested in additional modules for its COBAS 6000 analysis system to expand its biomarker analytical capabilities at its Poitiers facility in France. The company is now equipped to provide biomarker testing services across a range of instrument platforms for both multiplexing and single analyte testing.

The Roche COBAS system 6000 was made available at SGS's Poitiers site in June 2014. It was initially equipped with the clinical chemistry module for small molecule and analyte testing. With the recent investment, SGS can offer additional services such as an immunoassay module for the quantification of cytokines, hormones, and other biomarkers for a range of diseases including oncology, sepsis, anemia, and endocrinology. The new module complements the existing platforms, supporting drug development of biomarkers for various applications.

The system only requires a small amount of clinical sample and sample integrity is maintaind as the testing process is fully automated. The high throughput methods enable faster run times and turnarounds. According to SGS, the system offers high sensitivity, precision, and wide dynamic range. In additon, the reagents are qualified for lot consistency, minimizing the need for additional validation before testing of clinical samples.

Source: SGS